Glucocorticoid hormones were discovered to have use as potent anti-inflammatory and
immunosuppressive therapeutics in the 1940s and their continued use and development …

Chronic obstructive pulmonary disease (COPD) is the third leading cause of death
worldwide. While COPD is a mainly chronic disease, a substantial number of patients suffer …

This Executive Summary of the Global Strategy for the Diagnosis, Management, and
Prevention of COPD, Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2017 …

Objective This guideline provides evidence-based recommendations on treating patients
who present with dysphonia, which is characterized by altered vocal quality, pitch, loudness …

The efficacy, safety and positioning of inhaled corticosteroids (ICS) in the treatment of
patients with chronic obstructive pulmonary disease (COPD) is much debated, since it can …

By 2020, chronic obstructive pulmonary disease (COPD) will be the third cause of mortality.
Extrapulmonary comorbidities influence the prognosis of patients with COPD. Tobacco …

Background The long-term natural history of chronic obstructive pulmonary disease (COPD)
in terms of successive severe exacerbations and mortality is unknown. Methods The authors …

It is estimated that 2% to 3% of the population are currently prescribed systemic or topical
glucocorticoid treatment. The potent anti-inflammatory action of glucocorticoids to deliver …

Rationale: There are no studies on withdrawal of inhaled corticosteroids in patients on long-
term triple therapy in the absence of frequent exacerbations. Objectives: To evaluate the …

Background Inhaled corticosteroids (ICS) are known to increase the risk of pneumonia in
patients with chronic obstructive pulmonary disease (COPD). It is unclear whether the risk of …